PharmaBiz - “TOPIC Study Shows Once-Daily Aubagio Delay Onset of Clinically Definite Multiple Sclerosis”

New York, NY
 – May 28, 2013 /Press Release/  –– 

Genzyme, a Sanofi company has reported positive top-line results from the TOPIC trial for Aubagio (teriflunomide). The trial was designed to assess whether early initiation of Aubagio (teriflunomide) in patients who experienced their first neurological symptoms consistent with Clinically Isolated Syndrome (CIS) can prevent or delay conversion to clinically definite multiple sclerosis (CDMS). “Clinically Isolated Syndrome (CIS) is often a prelude to clinically definite multiple sclerosis, and early treatment has proved beneficial,” said Dr. Aaron E Miller, medical director, The Corinne Goldsmith Dickinson Centre for Multiple Sclerosis, The Mount Sinai Medical Center. “These findings are important as there is an unmet need for an efficacious oral option for patients at this stage of disease.” Learn more